{
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "document": {
    "pdf_name": "FlublokPI"
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 2
  },
  "extracted_evidence": [
    {
      "id": "comp_1",
      "quote": "An exploratory analysis of VE of Flublok against all strains, regardless of antigenic match, isolated from any subject with an ILI, not necessarily meeting CDC- ILI criteria, demonstrated an efficacy estimate of 44.8% (95% CI 24.4, 60.0).",
      "relevance_explanation": "This quote shows that Flublok provided efficacy against influenza strains regardless of whether they matched the vaccine, supporting the idea of cross-protection in a mismatch season.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "CDC surveillance data indicated that the majority of influenza A/H3 N2 wild type viruses were antigenic ally distinct whereas influenzaA/H1 N1 and type B viruses were antigenic ally similar to vaccine antigens during the 2014-2015 season. Study 6 met the pre specified success criterion for the primary endpoint (lower limit of the 2 sided 95% CI of vaccine efficacy for Flublok Quad rival ent relative to Comparator should be not less than 20%)",
      "relevance_explanation": "This quote indicates that even when the circulating H3N2 viruses were antigenically distinct (i.e., a mismatch), Flublok still met efficacy criteria, supporting the claim of broader immune response and cross-protection.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ]
}